Cargando…
A patient with maculopapular rash and lichenoid skin damage caused by ponatinib
Tyrosine kinase inhibitors (TKIs) are invaluable for the treatment of patients with chronic myelogenous leukemia. Although TKIs are generally better tolerated than traditional chemotherapy, dermatologic side effects are common and present a significant cause of concern for both patients and physicia...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7132818/ https://www.ncbi.nlm.nih.gov/pubmed/32242465 http://dx.doi.org/10.1177/0300060520903660 |
_version_ | 1783517512022884352 |
---|---|
author | Teigen, Ingrid Anna Sæle, Anna Kristine Myrmel Reikvam, Håkon |
author_facet | Teigen, Ingrid Anna Sæle, Anna Kristine Myrmel Reikvam, Håkon |
author_sort | Teigen, Ingrid Anna |
collection | PubMed |
description | Tyrosine kinase inhibitors (TKIs) are invaluable for the treatment of patients with chronic myelogenous leukemia. Although TKIs are generally better tolerated than traditional chemotherapy, dermatologic side effects are common and present a significant cause of concern for both patients and physicians. Ponatinib is a third-generation TKI and the only kinase inhibitor effective in patients with certain BCR-ABL1 mutations, including the T315I mutation. However, ponatinib is associated with an increased risk of serious side effects, and severe cutaneous reactions have increasingly been reported. We present a patient who developed a cutaneous lichenoid eruption following the initiation of ponatinib, which resolved after treatment with a topical retinoid. This case demonstrates that cutaneous side effects caused by ponatinib can be managed relatively easily, allowing patients to continue treatment with ponatinib. This is important considerting the limited alternative treatment approaches available for BCR-ABL1 T315I chronic myelogenous leukemia. |
format | Online Article Text |
id | pubmed-7132818 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | SAGE Publications |
record_format | MEDLINE/PubMed |
spelling | pubmed-71328182020-04-13 A patient with maculopapular rash and lichenoid skin damage caused by ponatinib Teigen, Ingrid Anna Sæle, Anna Kristine Myrmel Reikvam, Håkon J Int Med Res Case Report Tyrosine kinase inhibitors (TKIs) are invaluable for the treatment of patients with chronic myelogenous leukemia. Although TKIs are generally better tolerated than traditional chemotherapy, dermatologic side effects are common and present a significant cause of concern for both patients and physicians. Ponatinib is a third-generation TKI and the only kinase inhibitor effective in patients with certain BCR-ABL1 mutations, including the T315I mutation. However, ponatinib is associated with an increased risk of serious side effects, and severe cutaneous reactions have increasingly been reported. We present a patient who developed a cutaneous lichenoid eruption following the initiation of ponatinib, which resolved after treatment with a topical retinoid. This case demonstrates that cutaneous side effects caused by ponatinib can be managed relatively easily, allowing patients to continue treatment with ponatinib. This is important considerting the limited alternative treatment approaches available for BCR-ABL1 T315I chronic myelogenous leukemia. SAGE Publications 2020-04-03 /pmc/articles/PMC7132818/ /pubmed/32242465 http://dx.doi.org/10.1177/0300060520903660 Text en © The Author(s) 2020 https://creativecommons.org/licenses/by-nc/4.0/ Creative Commons Non Commercial CC BY-NC: This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage). |
spellingShingle | Case Report Teigen, Ingrid Anna Sæle, Anna Kristine Myrmel Reikvam, Håkon A patient with maculopapular rash and lichenoid skin damage caused by ponatinib |
title | A patient with maculopapular rash and lichenoid skin damage caused by ponatinib |
title_full | A patient with maculopapular rash and lichenoid skin damage caused by ponatinib |
title_fullStr | A patient with maculopapular rash and lichenoid skin damage caused by ponatinib |
title_full_unstemmed | A patient with maculopapular rash and lichenoid skin damage caused by ponatinib |
title_short | A patient with maculopapular rash and lichenoid skin damage caused by ponatinib |
title_sort | patient with maculopapular rash and lichenoid skin damage caused by ponatinib |
topic | Case Report |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7132818/ https://www.ncbi.nlm.nih.gov/pubmed/32242465 http://dx.doi.org/10.1177/0300060520903660 |
work_keys_str_mv | AT teigeningridanna apatientwithmaculopapularrashandlichenoidskindamagecausedbyponatinib AT sæleannakristinemyrmel apatientwithmaculopapularrashandlichenoidskindamagecausedbyponatinib AT reikvamhakon apatientwithmaculopapularrashandlichenoidskindamagecausedbyponatinib AT teigeningridanna patientwithmaculopapularrashandlichenoidskindamagecausedbyponatinib AT sæleannakristinemyrmel patientwithmaculopapularrashandlichenoidskindamagecausedbyponatinib AT reikvamhakon patientwithmaculopapularrashandlichenoidskindamagecausedbyponatinib |